Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01161394 · ClinicalTrials.gov registry record · Phase 4
Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study
A Phase 4 study, sponsored by University at Buffalo.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT01161394 is a Phase 4 study that has completed, run by University at Buffalo. The registered enrollment target is 24 participants.
The verdict
NCT01161394, a Phase 4 study, has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
Pioglitazone decreases oxidative load, inflammatory end points and improves vascular reactivity in obese patients in a dose dependent manner and that this effect is independent of its glucose lowering effects.
Interventions
- DRUG placebo
- DRUG Pioglitazone 15mg
- DRUG pioglitazone 30mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Est. Completion | 2003-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01161394
The ClinicalTrials.gov registry entry for NCT01161394 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01161394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01161394 about?
NCT01161394 is a clinical study titled "Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study". Pioglitazone decreases oxidative load, inflammatory end points and improves vascular reactivity in obese patients in a dose dependent manner and that this effect is independent of its glucose lowering effects.
What is the current status of trial NCT01161394?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. Estimated completion is 2003-10.
What interventions are being tested in trial NCT01161394?
The interventions under investigation include: placebo (DRUG), Pioglitazone 15mg (DRUG), pioglitazone 30mg (DRUG).
Who is sponsoring clinical trial NCT01161394?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.